insulin glargine vs Insulin sudelidec (INS068)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline

insulin glargine · Lantus

Marketed by Sanofi

Approved in Type 2 Diabetespeptide
Partial signal

NCT00069784 · Phase 3 · completed

The trial randomized 12,537 participants and used adjudicated clinical cardiovascular events, but treatment assignment was open-label rather than double-blinded. Neither primary cardiovascular endpoint was statistically significant in favor of insulin glargine, so the evidence supports a well-powered but inconclusive or negative finding rather than strong evidence of benefit.

Next expected readout: June 2027 · NCT07173712 (registry estimate)

No aligned efficacy figure on record for this race.

Insulin sudelidec (INS068)

Marketed by Jiangsu Hengrui Pharmaceuticals

Phase 3 in Type 2 Diabetespeptide
Partial signal

NCT05699408 · Phase 3 · completed

This Phase 3 trial randomly assigned 513 people with type 2 diabetes to insulin sudelidec or to insulin glargine, alongside their existing oral diabetes medicines. It was open-label, so treatment assignment was known throughout. HbA1c fell by 1.34 percentage points on insulin sudelidec against 1.37 on insulin glargine, a difference of 0.02 points (95% CI -0.14 to 0.18), meeting the prespecified test that it was not worse than glargine.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

Change in HbA1c (Week 0 to Week 26): Change in HbA1c at Week 26 (Study 302, oral-antidiabetic-drug background, n=513): insulin sudelidec (INS068) -1.34% vs insulin glargine -1.37%; between-group difference 0.02% (95% CI -0.14% to 0.18%) (met)

Result source: NCT05699408

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointinsulin glargineInsulin sudelidec (INS068)
HbA1c, change-0.6% vs -0.8%vs Insulin Icodecwk 26 · n 201NCT06340854
18 other results
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · primary NCT05462756
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · secondary NCT05462756
  • -1.7% vs -1.4% wk 26 · n 134 · Phase 4 · primary NCT00391027
  • -2.0% vs -1.8% wk 26 · n 154 · Phase 4 · primary NCT00418522
  • -1.7% vs -1.1% wk 24 · n 224 · Phase 4 · primary NCT00751114
  • -1.3% vs -1.4% wk 24 · n 30 · Phase 4 · primary NCT00686712
  • -1.9% vs -1.4% wk 24 · n 25 · Phase 4 · primary NCT00686712
  • -1.3% vs -1.4% wk 12 · n 46 · Phase 4 · primary NCT02455076
  • -1.1% vs -1.4% wk 12 · n 50 · Phase 4 · primary NCT02455076
  • -1.9% vs -1.7% wk 26 · n 203 · Phase 4 · secondary NCT00418522
  • -1.9% vs -1.8% wk 24 · n 467 · Phase 4 · secondary NCT01117350
  • -0.4% vs -0.1% wk 24 · n 49 · Phase 4 · secondary NCT00360698
  • -1.7% vs -1.5% wk 18 · n 134 · Phase 4 · secondary NCT00391027
  • -1.6% vs -1.3% wk 12 · n 134 · Phase 4 · secondary NCT00391027
  • -1.3% vs -1.1% wk 8 · n 134 · Phase 4 · secondary NCT00391027
  • -0.8% vs -0.6% wk 4 · n 134 · Phase 4 · secondary NCT00391027
  • -0.4% vs -0.3% wk 2 · n 134 · Phase 4 · secondary NCT00391027
  • -2.5% vs -2.1% wk 60 · n 144 · Phase 4 · secondary NCT00384085
-1.3% vs -1.4%avs insulin glarginewk 26NCT05699408
Body weight, change (kg)0.6 vs 2.0vs Insulin Icodecwk 26 · n 202NCT06340854
7 other results
  • 2.7 vs 2.5 wk 26 · n 365 · Phase 3 · secondary NCT05462756
  • 2.0 vs -3.0 wk 24 · n 474 · Phase 4 · secondary NCT01117350
  • 2.2 vs 1.1 wk 26 · n 125 · Phase 4 · secondary NCT00391027
  • 3.5 vs 2.3 wk 26 · n 203 · Phase 4 · secondary NCT00418522
  • 0.4 vs -1.1 wk 24 · n 227 · Phase 4 · secondary NCT00751114
  • 0.5 vs 0.2 wk 24 · n 48 · Phase 4 · secondary NCT00360698
  • -1 vs -0.5 n 42 · Phase 4 · secondary NCT02455076
—Not posted · NCT05699408
HbA1c below 7%48.4% vs 45.9%vs Liraglutidewk 24 · n 467NCT01117350
4 other results
  • 22.4% vs 8.8% wk 24 · n 49 · Phase 4 · primary NCT00360698
  • 51.1% vs 39.5% wk 60 · n 180 · Phase 4 · secondary NCT00384085
  • 62.6% vs 47.6% wk 26 · n 203 · Phase 4 · secondary NCT00418522
  • 67.9% vs 41.9% wk 24 · n 224 · Phase 4 · secondary NCT00751114
—Not posted · NCT05699408
Fasting plasma glucose, change-3.6 vs -2.1vs Liraglutidewk 24 · n 468NCT01117350
4 other results
  • -1.7 vs -3.3 wk 26 · n 134 · Phase 4 · secondary NCT00391027
  • -2.9 vs -3.0 wk 26 · n 203 · Phase 4 · secondary NCT00418522
  • -3.4 vs -1.1 wk 24 · n 214 · Phase 4 · secondary NCT00751114
  • -0.8 vs -0.8 wk 10 · n 154 · Phase 4 · secondary NCT01226043
—Not posted · NCT05699408
3-point MACE (% with event)—Not posted · NCT00044447—Not posted · NCT05699408

HbA1c, change

insulin glargine
-0.6% vs -0.8%vs Insulin Icodecwk 26 · n 201NCT06340854
18 other results
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · primary NCT05462756
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · secondary NCT05462756
  • -1.7% vs -1.4% wk 26 · n 134 · Phase 4 · primary NCT00391027
  • -2.0% vs -1.8% wk 26 · n 154 · Phase 4 · primary NCT00418522
  • -1.7% vs -1.1% wk 24 · n 224 · Phase 4 · primary NCT00751114
  • -1.3% vs -1.4% wk 24 · n 30 · Phase 4 · primary NCT00686712
  • -1.9% vs -1.4% wk 24 · n 25 · Phase 4 · primary NCT00686712
  • -1.3% vs -1.4% wk 12 · n 46 · Phase 4 · primary NCT02455076
  • -1.1% vs -1.4% wk 12 · n 50 · Phase 4 · primary NCT02455076
  • -1.9% vs -1.7% wk 26 · n 203 · Phase 4 · secondary NCT00418522
  • -1.9% vs -1.8% wk 24 · n 467 · Phase 4 · secondary NCT01117350
  • -0.4% vs -0.1% wk 24 · n 49 · Phase 4 · secondary NCT00360698
  • -1.7% vs -1.5% wk 18 · n 134 · Phase 4 · secondary NCT00391027
  • -1.6% vs -1.3% wk 12 · n 134 · Phase 4 · secondary NCT00391027
  • -1.3% vs -1.1% wk 8 · n 134 · Phase 4 · secondary NCT00391027
  • -0.8% vs -0.6% wk 4 · n 134 · Phase 4 · secondary NCT00391027
  • -0.4% vs -0.3% wk 2 · n 134 · Phase 4 · secondary NCT00391027
  • -2.5% vs -2.1% wk 60 · n 144 · Phase 4 · secondary NCT00384085
Insulin sudelidec (INS068)
-1.3% vs -1.4%avs insulin glarginewk 26NCT05699408

Body weight, change (kg)

insulin glargine
0.6 vs 2.0vs Insulin Icodecwk 26 · n 202NCT06340854
7 other results
  • 2.7 vs 2.5 wk 26 · n 365 · Phase 3 · secondary NCT05462756
  • 2.0 vs -3.0 wk 24 · n 474 · Phase 4 · secondary NCT01117350
  • 2.2 vs 1.1 wk 26 · n 125 · Phase 4 · secondary NCT00391027
  • 3.5 vs 2.3 wk 26 · n 203 · Phase 4 · secondary NCT00418522
  • 0.4 vs -1.1 wk 24 · n 227 · Phase 4 · secondary NCT00751114
  • 0.5 vs 0.2 wk 24 · n 48 · Phase 4 · secondary NCT00360698
  • -1 vs -0.5 n 42 · Phase 4 · secondary NCT02455076
Insulin sudelidec (INS068)
—Not posted · NCT05699408

HbA1c below 7%

insulin glargine
48.4% vs 45.9%vs Liraglutidewk 24 · n 467NCT01117350
4 other results
  • 22.4% vs 8.8% wk 24 · n 49 · Phase 4 · primary NCT00360698
  • 51.1% vs 39.5% wk 60 · n 180 · Phase 4 · secondary NCT00384085
  • 62.6% vs 47.6% wk 26 · n 203 · Phase 4 · secondary NCT00418522
  • 67.9% vs 41.9% wk 24 · n 224 · Phase 4 · secondary NCT00751114
Insulin sudelidec (INS068)
—Not posted · NCT05699408

Fasting plasma glucose, change

insulin glargine
-3.6 vs -2.1vs Liraglutidewk 24 · n 468NCT01117350
4 other results
  • -1.7 vs -3.3 wk 26 · n 134 · Phase 4 · secondary NCT00391027
  • -2.9 vs -3.0 wk 26 · n 203 · Phase 4 · secondary NCT00418522
  • -3.4 vs -1.1 wk 24 · n 214 · Phase 4 · secondary NCT00751114
  • -0.8 vs -0.8 wk 10 · n 154 · Phase 4 · secondary NCT01226043
Insulin sudelidec (INS068)
—Not posted · NCT05699408

3-point MACE (% with event)

insulin glargine
—Not posted · NCT00044447
Insulin sudelidec (INS068)
—Not posted · NCT05699408
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. insulin glargine: 4 of 4 rows · Insulin sudelidec (INS068): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricinsulin glargineInsulin sudelidec (INS068)
Dropout rate
19.3%a
NCT00069784 · Phase 3
show 29 more results
11.3%
NCT05114590 · Phase 4 · registry result, not featured evidence
28.3%
NCT04153981 · Phase 4 · registry result, not featured evidence
1.3%
NCT02561130 · Phase 4 · registry result, not featured evidence
8.5%Exenatide Inpatient
NCT02455076 · Phase 4 · registry result, not featured evidence
—Exenatide Outpatient
NCT02455076 · Phase 4 · registry result, not featured evidence
2%Exenatide Plus Glargine Insulin In
NCT02455076 · Phase 4 · registry result, not featured evidence · combination
—Comparative Period: Insulin Glargi
NCT01117350 · Phase 4 · registry result, not featured evidence
—Extension Period: Insulin Glargine
NCT01117350 · Phase 4 · registry result, not featured evidence
8.6%Insulin Glargine
NCT01117350 · Phase 4 · registry result, not featured evidence
—Crossover Phase: SoloSTAR® Pen
NCT01226043 · Phase 4 · registry result, not featured evidence
—Observational Phase: SoloSTAR® Pen
NCT01226043 · Phase 4 · registry result, not featured evidence
—Re-randomization Phase: SoloSTAR®
NCT01226043 · Phase 4 · registry result, not featured evidence
—SoloSTAR® Pen
NCT01226043 · Phase 4 · registry result, not featured evidence
15.2%
NCT00751114 · Phase 4 · registry result, not featured evidence
12.3%0.5 Units/kg
NCT00911625 · Phase 4 · registry result, not featured evidence
0%0.25 Units/kg
NCT00911625 · Phase 4 · registry result, not featured evidence
23.5%Lantus/Apidra-1
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
20%Lantus/Apidra-3
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
33.3%Insulin Glargine at Bedtime
NCT00686712 · Phase 4 · registry result, not featured evidence
44%Insulin Glargine in AM
NCT00686712 · Phase 4 · registry result, not featured evidence
—
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
18.5%
NCT00391027 · Phase 4 · registry result, not featured evidence
37.9%
NCT00418522 · Phase 4 · registry result, not featured evidence
—
NCT00467649 · Phase 4 · registry result, not featured evidence · combination
1.5%
NCT06340854 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
—Efsitora
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
—Glargine
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
9.3%Insulin Glargine
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
4.7%
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
—
Discontinued due to AEs
1.7%a
NCT00069784 · Phase 3
show 29 more results
0.8%
NCT05114590 · Phase 4 · registry result, not featured evidence
—
NCT04153981 · Phase 4 · registry result, not featured evidence
—
NCT02561130 · Phase 4 · registry result, not featured evidence
6.4%Exenatide Inpatient
NCT02455076 · Phase 4 · registry result, not featured evidence
—Exenatide Outpatient
NCT02455076 · Phase 4 · registry result, not featured evidence
0%Exenatide Plus Glargine Insulin In
NCT02455076 · Phase 4 · registry result, not featured evidence · combination
—Comparative Period: Insulin Glargi
NCT01117350 · Phase 4 · registry result, not featured evidence
—Extension Period: Insulin Glargine
NCT01117350 · Phase 4 · registry result, not featured evidence
1.2%Insulin Glargine
NCT01117350 · Phase 4 · registry result, not featured evidence
—Crossover Phase: SoloSTAR® Pen
NCT01226043 · Phase 4 · registry result, not featured evidence
—Observational Phase: SoloSTAR® Pen
NCT01226043 · Phase 4 · registry result, not featured evidence
—Re-randomization Phase: SoloSTAR®
NCT01226043 · Phase 4 · registry result, not featured evidence
—SoloSTAR® Pen
NCT01226043 · Phase 4 · registry result, not featured evidence
0.8%
NCT00751114 · Phase 4 · registry result, not featured evidence
—0.5 Units/kg
NCT00911625 · Phase 4 · registry result, not featured evidence
—0.25 Units/kg
NCT00911625 · Phase 4 · registry result, not featured evidence
2.6%Lantus/Apidra-1
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
2.6%Lantus/Apidra-3
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
3.3%Insulin Glargine at Bedtime
NCT00686712 · Phase 4 · registry result, not featured evidence
4%Insulin Glargine in AM
NCT00686712 · Phase 4 · registry result, not featured evidence
—
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
5.9%
NCT00391027 · Phase 4 · registry result, not featured evidence
3.2%
NCT00418522 · Phase 4 · registry result, not featured evidence
—
NCT00467649 · Phase 4 · registry result, not featured evidence · combination
—
NCT06340854 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
—Efsitora
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
—Glargine
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
—Insulin Glargine
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
0.8%
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
—
Serious AEs
4.9%a
NCT00069784 · Phase 3
show 29 more results
0.8%
NCT05114590 · Phase 4 · registry result, not featured evidence
0.4%
NCT04153981 · Phase 4 · registry result, not featured evidence
3.9%
NCT02561130 · Phase 4 · registry result, not featured evidence
14.9%Exenatide Inpatient
NCT02455076 · Phase 4 · registry result, not featured evidence
22.9%Exenatide Outpatient
NCT02455076 · Phase 4 · registry result, not featured evidence
23.5%Exenatide Plus Glargine Insulin In
NCT02455076 · Phase 4 · registry result, not featured evidence · combination
2.3%Comparative Period: Insulin Glargi
NCT01117350 · Phase 4 · registry result, not featured evidence
3.1%Extension Period: Insulin Glargine
NCT01117350 · Phase 4 · registry result, not featured evidence
—Insulin Glargine
NCT01117350 · Phase 4 · registry result, not featured evidence
1%Crossover Phase: SoloSTAR® Pen
NCT01226043 · Phase 4 · registry result, not featured evidence
10.1%Observational Phase: SoloSTAR® Pen
NCT01226043 · Phase 4 · registry result, not featured evidence
0.6%Re-randomization Phase: SoloSTAR®
NCT01226043 · Phase 4 · registry result, not featured evidence
—SoloSTAR® Pen
NCT01226043 · Phase 4 · registry result, not featured evidence
6.3%
NCT00751114 · Phase 4 · registry result, not featured evidence
0%0.5 Units/kg
NCT00911625 · Phase 4 · registry result, not featured evidence
0%0.25 Units/kg
NCT00911625 · Phase 4 · registry result, not featured evidence
11.9%Lantus/Apidra-1
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
11.3%Lantus/Apidra-3
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
0%Insulin Glargine at Bedtime
NCT00686712 · Phase 4 · registry result, not featured evidence
4%Insulin Glargine in AM
NCT00686712 · Phase 4 · registry result, not featured evidence
2%
NCT00360698 · Phase 4 · registry result, not featured evidence · combination
5.9%
NCT00391027 · Phase 4 · registry result, not featured evidence
—
NCT00418522 · Phase 4 · registry result, not featured evidence
0%
NCT00467649 · Phase 4 · registry result, not featured evidence · combination
5.8%
NCT06340854 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
6.5%Efsitora
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
5.3%Glargine
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
—Insulin Glargine
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
6.8%
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
—
Most frequent reported AEs
a
hypoglycaemia 5.7%
upper respiratory tract infection 5.7%
NCT05114590 · Phase 4 · registry result, not featured evidence
show 22 more results
anaemia 1.9%
cough 0.4%
hyperglycaemia 0.4%
NCT04153981 · Phase 4 · registry result, not featured evidence
genitourinary infection 5.2%
abdominal pain 3.9%
injury 3.9%
NCT02561130 · Phase 4 · registry result, not featured evidence
nausea 10.6%
vomiting 2.1%
NCT02455076 · Phase 4 · registry result, not featured evidence
nausea 41.7%
vomiting 22.9%
NCT02455076 · Phase 4 · registry result, not featured evidence
nausea 9.8%
vomiting 5.9%
NCT02455076 · Phase 4 · registry result, not featured evidence · combination
nasopharyngitis 7.9%
headache 5%
diarrhoea 3.7%
NCT01117350 · Phase 4 · registry result, not featured evidence
nasopharyngitis 7.5%
diarrhoea 3.1%
headache 1.3%
NCT01117350 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 1.8%
nasopharyngitis 1.3%
sinusitis 1%
NCT01226043 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 8.8%
sinusitis 7.5%
oedema peripheral 5%
NCT01226043 · Phase 4 · registry result, not featured evidence
nasopharyngitis 3.6%
upper respiratory tract infection 2.4%
sinusitis 1.2%
NCT01226043 · Phase 4 · registry result, not featured evidence
headache 6.3%
influenza 3.4%
nasopharyngitis 3.4%
NCT00751114 · Phase 4 · registry result, not featured evidence
any infections and infestations 42.3%
any musculoskeletal and connective tissue disorders 22.7%
any gastrointestinal disorders 16.5%
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
any infections and infestations 34%
any musculoskeletal and connective tissue disorders 23.2%
any nervous system disorders 20.1%
NCT00384085 · Phase 4 · registry result, not featured evidence · combination
symptomatic hypoglycemia 76.7%
asymptomatic retinal hemorrhage 3.3%
urinary tract infection 0%
NCT00686712 · Phase 4 · registry result, not featured evidence
symptomatic hypoglycemia 96%
asymptomatic retinal hemorrhage 0%
urinary tract infection 0%
NCT00686712 · Phase 4 · registry result, not featured evidence
hypoglycaemia 70.4%
nasopharyngitis 13.3%
cough 6.7%
NCT00391027 · Phase 4 · registry result, not featured evidence
hypoglycaemia 67.9%
tremor 31.6%
dizziness 18.9%
NCT00418522 · Phase 4 · registry result, not featured evidence
nausea 11.1%
diarrhoea 5.6%
hypertension 5.6%
NCT00467649 · Phase 4 · registry result, not featured evidence · combination
nasopharyngitis 7.8%
diabetic retinopathy 7.3%
diarrhoea 1.9%
NCT06340854 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
influenza 7.3%
covid-19 5.3%
hypertension 5.3%
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
drug titration error 9.8%
urinary tract infection 6.3%
influenza 5.8%
NCT05662332 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
nasopharyngitis 6.3%
influenza 3.8%
NCT05462756 · Phase 3 · registry result, not featured evidence · Type 2 Diabetes · phase 3
—

Notes

  1. aPopulation comparability has not been reviewed for 25 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

insulin glargine

MACE 3-point Composite 16.6% (n=6264) vs 16.1% (n=6273) Standard Care
event count · % of participants
Participants with a composite endpoint
NCT00069784 · Phase 3 · converted to % from 1041 participants as posted
Time to CV Death 7.7% (n=6264) vs 7.6% (n=6273) Standard Care
event count · % of participants
Endpoint's composition: CV death
NCT00069784 · Phase 3 · converted to % from 484 participants as posted
Myocardial Infarction 4.7% (n=6264) vs 4.5% (n=6273) Standard Care
event count · % of participants
Endpoint's composition: nonfatal MI
NCT00069784 · Phase 3 · converted to % from 297 participants as posted
show 1 more result
4.1% (n=6264) vs 3.8% (n=6273) Standard Care*
Endpoint's composition: nonfatal MI
NCT00069784 · Phase 3 · converted to % from 257 participants as posted
MACE Broad 28.6% (n=6264) vs 27.5% (n=6273) Standard Care
event count · % of participants
Participants with a composite endpoint
NCT00069784 · Phase 3 · converted to % from 1792 participants as posted
Coronary Revascularization 12.2% (n=6264) vs 11.4% (n=6273) Standard Care
event count · % of participants
Endpoint's composition: revascularization
NCT00069784 · Phase 3 · converted to % from 763 participants as posted
Microvascular Composite 21.1% (n=6264) vs 21.7% (n=6273) Standard Care
event count · % of participants
Participants with a composite endpoint
NCT00069784 · Phase 3 · converted to % from 1323 participants as posted
Albuminuria Progression 18.4% (n=6264) vs 18.7% (n=6273) Standard Care
event count · % of participants
Endpoint's composition: albuminuria progression
NCT00069784 · Phase 3 · converted to % from 1153 participants as posted
Type 2 Diabetes Incidence 24.7% (n=737) vs 31.2% (n=719) Standard Care
event rate · % of participants
NCT00069784 · Phase 3
Time in Range 24 h 26.22 % of time @ 16wk
absolute change · % of time
No placebo or comparator arm
NCT05114590 · Phase 4 · registry result, not featured evidence
Glucose Variability CV 5% (n=113) @ 16wk
absolute change · percentage points
No placebo or comparator arm
NCT05114590 · Phase 4 · registry result, not featured evidence
Daily Plasma Glucose Change mg/dL -2.91 mmol/L @ 16wk
absolute change · mmol/L
No placebo or comparator arm
NCT05114590 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -52.48 mg/dL as posted
PMG Change mg/dL -73.66 mg/dL @ 16wk
absolute change · mg/dL
No placebo or comparator arm
NCT05114590 · Phase 4 · registry result, not featured evidence

+ 65 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: insulin glargine's landscape · Insulin sudelidec (INS068)'s landscape